# Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

> **NCT00082498** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 119 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** SCH-D (vicriviroc)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00082498
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-12
- **Final completion:** 2011-01
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082498, "Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00082498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*